z-logo
open-access-imgOpen Access
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
Author(s) -
Satoshi Komiyama,
Kazushi Numata,
Satoshi Moriya,
Hiroyuki Fukuda,
Makoto Chuma,
Shin Maeda
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i12.2574
Subject(s) - lenvatinib , medicine , sorafenib , hepatocellular carcinoma , liver function , gastroenterology , oncology , radiology
In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma (uHCC), the drug proved non-inferior to sorafenib in terms of the overall survival, but offered better progression-free survival. However, the effects of lenvatinib in uHCC patients with a tumor thrombus in the main portal vein and/or a high tumor burden (tumor occupancy more than 50% of the total liver volume), remain unclear, because these were set as exclusion criteria in the aforementioned trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here